secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001558370-24-008918
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Coherus BioSciences appoints Rita A. Karachun to Board of Directors
-------------------------------------------------------------------

- Board size increased from 10 to 11; Karachun appointed as Class II director effective May 31, 2024.
- To serve on Audit Committee; received option for 168,000 shares vesting over 3 years.
- Previously SVP & Global Controller at Merck & Co. (2014-2023).
- Annual cash retainer of $60k for board and audit committee service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024008918/0001558370-24-008918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024008918/chrs-20240531x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer